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ABSTRACT 
 
Pertussis-like toxins are secreted by several bacterial pathogens during infection. They belong 
to the AB5 virulence factors, which bind to glycans on host cell membranes for 
internalization. Host cell recognition and internalization are mediated by toxin B subunits 
sharing a unique pentameric ring-like assembly. Although the role of pertussis toxin in 
whooping cough is well-established, pertussis-like toxins produced by other bacteria are less 
studied, and their mechanisms of action are unclear. Here, we report that some extra-
intestinal Escherichia coli pathogens (i.e. those that reside in the gut but can spread to other 
bodily locations) encode a pertussis-like toxin that inhibits mammalian cell growth in vitro. 
We found that this protein, EcPlt, is related to toxins produced by both nontyphoidal and 
typhoidal Salmonella serovars. Pertussis-like toxins are secreted as disulfide-bonded 
heterohexamers in which the catalytic ADP-ribosyltransferase subunit is activated when 
exposed to the reducing environment in mammalian cells. We found here that the 
reduced EcPlt exhibits large structural rearrangements associated with its activation. We 
noted that inhibitory residues tethered within the NAD+-binding site by an intramolecular 
disulfide in the oxidized state dissociate upon the reduction and enable loop restructuring to 
form the nucleotide-binding site. Surprisingly, although pertussis toxin targets a cysteine 
residue within the α subunit of inhibitory trimeric G-proteins, we observed that 
activated EcPlt toxin modifies a proximal lysine/asparagine residue instead. In conclusion, 
our results reveal the molecular mechanism underpinning activation of pertussis-like toxins, 
and we also identified differences in host target specificity. 
 
 
INTRODUCTION 
  
Pathogenic Escherichia coli strains preferentially inhabit different sites within their hosts, 
with enteric or extra-intestinal niches presenting distinctly different challenges. Infection by 
enteric or diarrheagenic E. coli can result in gastroenteritis, but it seldom spreads beyond the 
intestinal tract except in immunocompromised individuals (1, 2). In contrast, extra-
intestinal E. coli (ExPEC)7 strains such as uropathogenic E. coli (UPEC) or neonatal 
meningitis E. coli can reside passively within the gut until conditions permit their expansion 
into the urinary tract, blood, or nervous system where they may potentially cause life-
threatening disease (3). To do so, ExPEC strains express a range of virulence factors, often 
encoded on mobile genetic elements, including AB5 toxins. Such phage-encoded toxins are 
secreted by several major bacterial pathogens, including enterotoxigenic E. coli (55) and 
enterohemorrhagic E. coli (4); Vibrio cholerae(5), Shigella (6), Salmonella (7), 
and Bordetella pertussis (8, 9). Modern sequencing techniques frequently identify novel 
AB5 toxins related to those previously studied, but their conservation at the level of function 
remains to be determined. 
 
AB5 virulence factors bind to glycans present on the surface of eukaryotic host cell 
membranes resulting in their internalization. Once inside the host cell, the enzymatic A 
subunits are released allowing them to disrupt host biochemistry and physiology. Host cell 
recognition and internalization are mediated by the toxin B subunits that share a unique 
pentameric ring-like assembly. This juxtaposes with the A subunit cargos that are class-
specific and structurally divergent, and their activation inside mammalian cells occurs 
through distinct intracellular detection and release mechanisms (10). Five AB5 toxin families 
currently exist: the enzymatic components of the subtilase cytotoxin (11) and EcxAB toxin 
(12) are proteases, whereas those of the Shiga group (6) are ribosome inhibitors; cholera and 
heat-labile enterotoxins (4, 5) carry related ADP-ribosyltransferases, as do the related 
pertussis (8, 9) and typhoid toxin (7) proteins. 
 
Toxin ADP-ribosyltransferases (ARTs) hydrolyze the nicotinamide group from NAD+and 
transfer the ADP-ribose moiety onto specific host proteins. Pertussis toxin specifically targets 
inhibitory trimeric G-proteins by modifying a conserved cysteine located four residues from 
the C termini of the Gα subunit (13). This modification renders the Gαi/o subunits unable to 
associate with their cognate G-protein-coupled receptors (GPCRs) thus modulating the host's 
immune response. A series of related pertussis-like (Plt) toxins exist within the genomes of 
pathogenic bacteria, including strains of E. coli, Salmonella, and Yersinia. The bacterial 
strains harboring such virulence factors are diverse, and their evolutionary relationship is 
complicated due to the spread of these genes on mobile genetic elements. Proteins within the 
Plt family include the atypical archetype member whose glycan-binding B subunits have 
expanded and diverged within the B. pertussis genome to form four separate genes yielding a 
pseudopentameric glycan-binding platform. In contrast, other pertussis-like toxins display a 
homopentameric glycan-binding stoichiometry. All Plt proteins nonetheless carry a conserved 
catalytic A subunit. 
 
In the secreted state, the enzymatic ART domain of pertussis-like toxins lies atop the five 
glycan-binding subunits allowing its C terminus to thread through a U-shaped NAD+-binding 
cleft before plunging into the pore of the B subunit pentamer (7, 9). When these C-terminal 
residues are truncated from pertussis toxin, its ART domain is constitutively active in 
vitro but is unable to associate with its pseudopentamer or enter cells (14). Enzymatic 
activation in vivo requires proteolytic separation of the inhibitory C terminus and reduction of 
a connecting disulfide. Although the molecular mechanisms underlying an alternative 
activation mechanism of cholera toxin are understood (15), the changes that occur following 
activation of a pertussis-like protein have not previously been characterized. 
 
Although the association of pertussis toxin with whooping cough is well-established, 
orthologous pertussis-like toxins present within other pathogenic bacterial infections are less 
studied, and their mechanism(s) of action are unclear (7). Here we identify a pertussis-like 
AB5 protein (EcPltAB) from clinical E. coli isolates that is related to the typhoid and ArtAB 
toxins observed in typhoidal and nontyphoidal Salmonella serovars. We provide structures 
that confirm that pertussis-like toxins are secreted as inactive forms in which an 
intramolecular disulfide holds an occluding C-terminal tail within the NAD+-binding site. 
This conserved disulfide also serves as a redox switch that senses host cell entry, with 
reduction of the bond allowing displacement of the occluding C-terminal residues, facilitating 
NAD+ binding and maturation of catalytic activity. At a global level, the existence 
of EcPltAB-type proteins, and their relatives (55) expands the family of known bacterial 
pertussis-like toxins capable of modulating the human immune system. Furthermore, we 
show that although AB5 proteins are segregated into evolutionarily related enzyme families, 
these may not always modify the same residues within host proteins. 
 
 
RESULTS 
 
Identification of EcPltAB 
 
The frequency with which pathogenic bacterial strains are isolated from clinical settings does 
not necessarily correlate with their representation in genomic databases, yet it remains a 
useful proxy measure. We thus determined the prevalence of genes encoding AB5-type toxins 
among complete and draft E. coli genome sequences available on the NCBI database. E. 
coli genomes were queried using previously identified A and B subunit sequences. As 
expected, most genes discovered corresponded to previously known E. coli toxins; by far the 
most prevalent were the Shiga toxins produced by Shiga toxigenic E. coli, proteins whose 
action can cause hemolytic-uremic syndrome following infection, identified in 19% of 
genomes (supplemental Fig. S1). The next most prevalent were toxins from the cholera 
family LT-I and LT-II heat-labile enterotoxins secreted by enterotoxigenic E. coli (Fig. 1), 
identified in ∼8% of the genomes. The properties of these enteric E. coli toxins are well-
established (4, 5, 11). However, the third most common set of AB5 genes identified was a 
series of related pertussis-like proteins found in ExPEC genomes, particularly from 
phylogroup B2 (Fig. 1). The B subunit of these toxins shared 69% sequence identity 
to ArtB and the upstream A subunit 70% identity to ArtA, two components of a pertussis-like 
toxin produced by Salmonella typhimurium DT104 (16). In contrast to these Salmonella 
and Escherichia orthologs, the archetype pertussis toxin has an expanded set of four glycan-
binding B subunits (named S2–S5) associated with a single catalytic A or S1 subunit. 
The Salmonella ArtAB protein is an active ADP-ribosyltransferase (17), whereas a related 
typhoid toxin additionally serves as a cargo carrier for an accessory cytolethal distending 
toxin (7). Our analysis indicates that the E. coli Plt toxins are more evolutionarily diverse 
than the currently identified Salmonella variants, with at least three semi-separate lineages 
sharing between 70 and 80% sequence identity. We refer to the product of these pertussis-like 
genes as E. coli-pertussis-like toxins (EcPlt). 
 
 
 
 
Cytotoxicity of EcPltAB 
 
We characterized the EcPlt toxin family by cloning a number of representative members and 
expressing them using standard recombinant techniques, focusing primarily on the EcPlt 
genes (E9YZW8 and E9YZW9) cloned from UPEC isolate PA26B. The oxidized EcPltAB 
holotoxin was purified after co-expressing both subunits using a periplasmic expression 
system (18). The 96-kDa soluble protein complex eluted on gel filtration with a molecular 
mass consistent with that of an AB5 heterohexameric stoichiometry. To ascertain whether this 
holotoxin was functional, it was added to human embryonic kidney (HEK293T) or African 
green monkey kidney epithelial cells (Vero). Mammalian cell lines grown to 40–50% 
confluency were exposed to different concentrations of EcPltAB (Fig. 2a and supplemental 
Fig. S2). The characteristic response profile of pertussis toxin involves a slow cellular entry 
mechanism followed by an accumulative interruption of signaling resulting in clustered 
growth (19). Over an 18-h period, control-treated cells remained unaffected and continued to 
proliferate, although those exposed to EcPltAB displayed cell clustering and an absence of 
growth (see supplemental Fig. S2, a–c) compared with buffer-alone controls (supplemental 
Fig. S2d). 
 
Next, we performed a glycan array analysis to determine the specificity of EcPltAB 
(see supplemental Table S1). Its B subunit displayed avidity for a broad range of branched 
eukaryotic glycans, especially those with N-acetylneuraminic acid (Neu5Ac) termini, thus 
implying EcPlt targets a similar range of cell types as typhoid toxin (7). 
 
We next sought to establish which eukaryotic proteins were targeted by EcPltA. The EcPltA 
toxin shares 50–70% identity with Salmonella ArtA proteins and 31% identity with the 
pertussis toxin's catalytic S1 subunit, two known ADP-ribosyltransferases that modify the α 
subunits of inhibitory trimeric GTP-binding proteins (17, 20). We set up an assay to identify 
equivalent EcPltA substrates by using biotin-conjugated NAD+ as substrate for the toxins. In 
such assays, ADP-ribosylation also adds a biotin tag to protein substrates that can then be 
imaged by Western blotting using streptavidin-horseradish peroxidase. Holotoxin (EcPltAB 
or PT) versions of this assay are dependent upon toxin activation and ADP-ribosylation rate, 
although when the assay is performed with constitutively active proteins (EcPltA or PT S1), 
only the ADP-ribosylation rate is measured.  
 
Using radiolabeled substrate, other groups (20) have shown that the PT holotoxin is activated 
by the presence of ATP and reducing agents. Our own ADP-ribosylation assay recapitulates 
this result with a 41-kDa band being modified by PT in crudely purified trimeric G-protein 
brain extracts or Vero cell lysates under identical conditions (Fig. 2). A similar band was 
observed in reactions containing the EcPltAB holotoxin (Fig. 2). In both reactions, a major 
band at ∼41 kDa was ADP-ribosylated and migrated close to the molecular weight of PT-
treated Gαi proteins (Fig. 2b, left panel). To confirm that EcPltA targeted Gαi subunits, we 
cloned two HsGαi3 constructs (the most readily expressed isoform): the full-length protein 
and a more soluble construct lacking the N-terminal aliphatic helix (HsGαi3ΔN). Following 
expression and purification, full-length HsGαi3 acted as substrate for the toxin's ADP-
ribosyltransferase activity and migrated at a similar molecular weight to a band modified in 
Vero cell extracts, whereas other proteins within the Coomassie-stained lysate did not (Fig. 
2b, right panel). Both the full-length protein and Gαi3 ΔN-mutant served equally well as 
substrates for PT or EcPlt (supplemental Fig. S3), the latter Gαi3ΔN construct was favored for 
routine assays due to its enhanced stability. 
 
PT is responsible for many of the pathogenic features of B. pertussis. However, 
other Bordetella species also contain ptx-like genes yet fail to produce the toxin because of 
inactive promoters (21). Using our assay, we sought to identify whether ADP-
ribosyltransferase activity was detectable in the supernatant of UPEC strain PA26B. UPEC 
PA26B was cultured in the presence of prophage-inducing agents
.
 After 12 h of growth, 
bacterial cells were removed by filtration, and the supernatant was tested for ADP-
ribosyltransferase activity using HsGαi3ΔN as a substrate. In control reactions employing 
purified EcPltAB, a robust ADP-ribosyltransferase response was observed using 20 nM pure 
toxin (Fig. 2c, 1st lane). Prior to commencing the reaction, the supernatant of PA26B cells 
was seen to contain a natively biotinylated 20-kDa protein, but this was readily 
distinguishable from our host HsGαi3ΔN target (Fig. 2c, 2nd lane). When HsGαi3ΔN was 
added to the filtered supernatant of PA26B, we observed ADP-ribosylation of the substrate 
(Fig. 2c, 3rd lane) suggesting, but not conclusively proving, that EcPltAB is actively 
expressed. 
 
The B subunit of the typhoid toxin impacts cell-signaling pathways independent of its 
associated catalytic A subunits (22). To determine whether the growth-arrest phenotype 
induced by EcPltAB resulted from its enzymatic activity, inactivating mutations were 
incorporated into the A subunit. A highly conserved (Q/E)XE motif is present in many ADP-
ribosyltransferases and is essential for activity (23) (residues 116QNE118 in EcPltA). Mutation 
of residue Glu-118 to an aspartic acid residue resulted in a requirement for 1000-fold higher 
concentrations of toxin to induce the same level of growth arrest as wild-type EcPltAB toxin 
(Fig. 2d). Furthermore, a Q116D,E118D double mutant that retains a wild-type B subunit 
showed no effect on growth and was indistinguishable from control reactions even at 50 
μg/ml toxin (Fig. 2d and supplemental Fig. S2e), and as discussed later, this mutant displayed 
no discernible enzymatic activity (Fig. 7c). EcPltAB thus appears to be expressed by ExPEC, 
and its ADP-ribosyltransferase activity is cytotoxic to mammalian cells. 
 
The presence of ATP, phosphate, and detergent assists with activation of the PT S1 subunit 
by promoting dissociation from its pseudopentamer and increasing its exposure to the local 
microenvironment (24). ATP binds within the central pseudopentameric pore of the pertussis 
toxin, destabilizing the quaternary structure (25). We sought to determine whether the 
activation requirements for the EcPltAB toxin were similar. Our assay recapitulated the 
finding that reducing agents activate PT and that this process is synergistically enhanced by 
the presence of ATP (Fig. 3a, 1st to 5th lanes). Like PT, the EcPltAB holotoxin is inactive 
when oxidized, and higher concentrations of reducing agent result in increased catalytic 
activity in vitro (Fig. 3a, 6th to 8th lanes). However, ATP did not synergistically enhance this 
process (in Fig. 3a, 4th lane is 95% more intense than 2nd lane, although the intensities of 
the 7th and 9th lanes are within 1%). The ATP-binding site of the PT pseudopentamer 
appears absent within the homopentameric EcPltAB. We examined whether the nature of the 
reducing agent affected EcPltAB activation by repeating the ADP-ribosylation assays in the 
presence of intracellular (2 mM) or serum (2 μM) concentrations of glutathione using 
different redox ratios. Reduced glutathione alone was ∼20% more effective at inducing toxin 
activation in vitro than an equivalent concentration of TCEP (Fig. 3c), yet even small 
quantities of oxidized glutathione (GSSG) drastically slowed activation. Thus, although some 
characteristics are shared, the sequence divergence that exists between pertussis toxin and 
pertussis-like toxins results in differences in their respective activation mechanisms. 
 
Protein substrates 
 
PT targets the α subunits of human inhibitory trimeric G-proteins by transferring the ADP-
ribose moiety of NAD+ onto a conserved cysteine four residues from their C termini. PT-
sensitive substrates primarily belong to the heterotrimeric Gi/Go protein subfamily, which in 
humans includes the 40.5-kDa proteins Gαi1, Gαi2, Gαi3, and Gαio, as well as the equivalent 
subunit from transducin. The Salmonella ArtA pertussis-like toxin modifies this same set of 
proteins (17), indicating some degree of target conservation. As the HsGαi3 was shown to be 
an EcPltA substrate, we sought to test for activity against the remaining trimeric Gi proteins 
enriched from brain lysate using equal amounts of a commercial Gβ-immunoprecipitated 
source of trimeric inhibitor G-proteins. Mammalian inhibitory Gαi proteins possess similar 
molecular weights but have divergent pI values (Gαi2/Gαo (5.34), Gαi3 (5.50), and 
Gαi1 (5.7)), allowing for their separation as three distinct bands on an isoelectric focusing 
gel. PT-catalyzed ADP-ribosylation of brain lysate (Fig. 3c, left panel) showed three 
distinguishable IEF bands, roughly reproducing its substrate preference of Gαi2/Gαo > 
Gαi3 > Gαi1 (17). In contrast, when the same experiment was performed using EcPltA, at 
least three subunits were modified, with a slight relative preference for Gαi3 over 
Gαi2/Gαo and Gαi1 (Fig. 3c, right panel). EcPlt thus represents a functional AB5 toxin that 
retains some, but not all, characteristics of the archetypical PT. 
 
Protein substrate ADP – ribosylation site 
 
Pertussis toxin specifically modifies a conserved cysteine four amino acids from the C 
terminus of Gαi/o subunits (26) (Cys-351) and in doing so renders them unable to interact 
with their cognate receptors (Fig. 4a). In our ADP-ribosyltransferase assay, and as reported 
by others (27), C351S mutations within the Gαi/o proteins leave them resistant to PT 
modification but surprisingly no modification by EcPltA (see Fig. 4b). To determine 
whether EcPltA targeted another cysteine residue, we mutated each cysteine residue and 
repeated the experiment; all such HsGαi3 mutants were simultaneously treated with PT as a 
control. As shown in Fig. 4b, all other cysteine knock-out mutants act equally well as 
substrates for either toxin. When cholera toxin's primary site of modification within 
stimulatory Gαs proteins is removed, lower affinity sites instead become targeted (28). In 
case EcPltA targeted more than one cysteine, we pretreated HsGαi3 with iodoacetamide for 
24 h and re-purified the protein prior to the assay (Fig. 4c). Alkylating all available cysteines 
renders HsGαi3 resistant to PT modification as expected, but it does not prevent the protein 
from being a substrate for EcPltA, indicating an alternative chemical linkage. The ADP-
ribosylation products produced by EcPltA and PT were not sensitive to 1 M hydroxylamine 
treatment suggesting the modification is on residues other than Glu and Asp. However, lysine 
methylation of HsGαi3 rendered it entirely resistant to EcPltA modification (Fig. 4c). PT 
could still act on methylated HsGαi3 substrate but at a slightly reduced rate compared with 
controls (Fig. 4c). 
 
To identify the residue(s) within HsGαi3 modified by EcPltA, the reaction product was 
subjected to MS-MS analysis. ADP-ribosylation results in a +541-Da mass shift to precursor 
peptides, and fragmentation of the pyrophosphate bond also liberates a characteristic 348.1-
Da adenine monophosphate during product ion scans (supplemental Fig. S4). We obtained 
full peptide coverage of HsGαi3 and could not detect any evidence of cysteine modification, 
instead ADP-ribosylated modification sites were identified in HsGαi3 C-terminal 
sequences: 331NVQFVFDAVTDVII-K(ADP-ribosylated)-NNLK349 and 346NN-(ADP-
ribosylated)-LKECGLY354. Thus, EcPltA ADP-ribosylates two residues (Lys-345 and Asn-
347) at the C terminus of HsGαi3, sites distinct from PT modification of Cys-351. We next 
constructed three mutants, HsGαi3(K345A), HsGαi3(N346A), and HsGαi3(N347A), and 
tested their suitability as substrates for both toxins. HsGαi3(K345A) was seen to be resistant 
to ADP-ribosylation by EcPltA, yet it was readily modified by the constitutively active PT S1 
(Fig. 4d); HsGαi3(N346A) was readily ADP-ribosylated by either toxin and HsGαi3(N347A) 
by neither toxin (Fig. 4e). It is noteworthy that mutation of either Lys-345 or Asn-347 to 
alanine also reduced enzymatic activity against the other site, suggesting a concerted 
mechanism of recognition. Together, these experiments suggest that different pertussis-like 
toxins can target distinct but nearby residues within the C termini of Gαiproteins. 
 
Gαi/o recruitment to GPCRs is disrupted by EcPltAB 
 
We next examined what effect EcPltAB had on GPCR-signaling pathways in cells. The 
Relaxin family peptide 4 receptor (RXFP4) is a GPCR that recruits Gαi/o subunits upon 
binding its ligand: insulin-like peptide 5 (INSL5); the induced nucleotide exchange inhibits 
forskolin-stimulated cAMP production and promotes ERK phosphorylation (29), a response 
that can be abolished through PT pretreatment. Gαi/o proteins with a C351I mutation 
(mGαoA, mGαoB, mGαi1, mGαi2, or mGαi3) are PT-insensitive and can be used to rescue 
the PT-abolished INSL5-stimulated ERK1/2 response to determine which Gαi/o subunits are 
recruited to RXFP4. We first confirmed that PT could completely abrogate the INSL5-
stimulated ERK1/2 response within Chinese hamster ovary (CHO)-RXFP4 cells transfected 
with the pcDNA3 vector control (Fig. 5a); an identical result was obtained with EcPltAB 
pretreatment (Fig. 5a). Next, we demonstrated that ERK1/2 responses were partially restored 
in PT-treated cells transfected with mGαoA, mGαoB, mGαi2, and to a smaller extent with 
mGαi3 but negligibly with Gαi1 (Fig. 5, b–f). GPCR RXFP4 can thus recruit all isoforms of 
Gαi/o, although it does so in a preferential manner, predominantly recruiting GαoA = 
GαoB = Gαi2 > Gαi3 ≥ Gαi1. None of the PT-insensitive Gαi/o mutants tested were able to 
restore INSL5-stimulated ERK1/2 responses in cells treated with EcPltAB (Fig. 5, b–f), 
underlining that within cells the residue(s) on Gαi/o targeted by EcPltAB differ from the 
canonical Cys-351 ADP-ribosylated by PT and that once modified the GPCR signaling is 
disrupted. 
 
As Gαi/o subunits carrying the PT-resistant C351I mutant remain sensitive to EcPltAB 
treatment, we next sought to identify alternative EcPlt-resistant mutations. To do so we 
monitored the cAMP concentration in cells responding to the adenylyl cyclase activator 
forskolin (supplemental Fig. S5a). This stimulatory response can be counteracted by 
inhibitory trimeric G-proteins coupled to INSL5-induced RXFP4 signaling, which acts to 
restore cAMP levels to a near basal state (supplemental Fig. S5a). The RXFP4-transduced 
inhibitory signal can be abrogated by either toxin (supplemental Fig. S5a), and reconstituting 
C351I Gαi/o subunits allows partial recovery of the inhibitory signal in the presence of PT 
(supplemental Fig. S5, b–f) but not EcPltAB. In an attempt to achieve an equivalent response 
for the enterobacterial toxin, we mutated its two identified ADP-ribosylation sites 
within HsGαi3 to alanine (N347A and K345A) and repeated the experiment (supplemental 
Fig. S5, g and h). Neither HsGαi3(N347A) nor HsGαi3(K345A) facilitated the recovery of 
PT-treated cells. In contrast, EcPltAB treatment of cells transfected with HsGαi3(N347A) 
displayed a 26 ± 5% difference in the cAMP response in the presence of INSL5/forskolin or 
forskolin alone (supplemental Fig. S5g), consistent with the N347A mutant providing a 
degree of protection for EcPltAB but not for PT. In the same experiment, HsGαi3(K345A) 
did not obviously allow recovery of INSL5-mediated signaling (Fig. 7h). 
 
Structure of the secreted EcPltAB holotoxin 
 
To understand the secreted ExPEC toxins in more detail, we determined the 2.4 Å crystal 
structure of the EcPltAB holotoxin (see supplemental Methods and Table 1 for details). This 
heterohexameric complex resembles a blunted pyramid in which the EcPltA subunit sits atop 
a pentameric B subunit base, thereby adopting an overall quaternary structure of the 
AB5 family (Fig. 6a). In the secreted oxidized state, the enzymatic A subunit contains a 
single intramolecular disulfide bond between the two conserved cysteines (Cys-41 and Cys-
192, Fig. 6b); each of the five EcPltB subunits contains a further two intramolecular 
disulfides. EcPltA shares 52% sequence identity to the typhoid toxin's A subunit (30) and 
31% identity to the S1 subunit of pertussis toxin (9), its two closest known structural 
homologs (root mean squared deviation of 1.1 Å over 207 of 224 Cα; and 2.0 Å over 186 Cα, 
respectively PDBeFOLD). In all three holotoxins, the respective orientation of the A subunit 
atop the B pentamer is similar, with the Cα backbone structure of the EcPlt holotoxin and the 
lower AB5 section of the typhoid toxin overlaying over most of their length. The conserved 
intramolecular disulfide of pertussis group toxins holds their inhibitory C-terminal residues 
inside their nucleotide-binding sites (Fig. 6b), preventing catalytic activity prior to entry into 
the reducing environment of the host cytoplasm. 
 
Structure of the cytoplasmic NAD+-bound EcPltA 
 
To determine what structural changes occur following release of the C-terminal redox switch, 
we determined a 1.8-Å resolution structure of the constitutively active catalytic EcPltA 
subunit (residues 5–181) purified under reducing conditions (Table 1). As ART enzymes 
display off-target NAD+-glycohydrolase activity in the absence of substrate, we utilized the 
catalytically inactive mutant (Q116D,E118D) to slow this reaction and permit stable co-
complex formation with the NAD+ substrate (30). These crystals diffracted in space group P1 
with four complexes of NAD+–EcPltAcat within the asymmetric unit allowing independent 
models of the ART domain to be compared. The enzymatic core of the ART fold consists of ∼150 amino acids and has a U-shape with a concave cleft creating the NAD+-binding site 
(Fig. 6c). The two β-sheets of EcPltA are on either side of this nucleotide-binding cleft: on 
one side is the β-sheet with strands s1, s3, s6, and s7 sandwiched between helix 3 and helix 1, 
and on the other side is the fold's smaller s2, s5, and s4 β-sheet along with its h2, h4, and h5 
helices. Unbiased omit maps showed NAD+ to be bound inside the U-shaped ART domain 
with two distinct binding modes observed, one extended and the other semi-extended (Fig. 7) 
(31). The extended conformation (supplemental Fig. S6a) dominates in the A, B, and C 
protomers and the semi-extended conformation in D (supplemental Fig. S6b). Both bound 
forms of NAD+ adopt highly folded nicotinamide mononucleotide (NMN) sections, whereas 
the adenine base transits between alternative aromatic stacking interactions. The common 
factor within the two distinct nucleotide conformations is the folded NMN group, and forcing 
the nucleotide to adopt this form is proposed to be an integral part of catalysis (32). The 
residues stabilizing the compact NMN are contributed from both sides of the binding cleft. 
Strand s1 provides a conserved phosphate-binding nucleophilic amino acid (Arg-9) also 
found in PT, although the amide group of the nicotinamide moiety forms hydrogen bonds to 
the peptide backbone (Fig. 7a). On the other side of the cleft, residues within a semi-
conserved “STS” motif within the s2 strand position the scissile bond for catalysis by 
clasping the nicotinic ring of NAD+ (actual residues 52ATT54, supplemental Fig. S6c). The 
inactivating E118D mutation of the catalytically essential glutamate shifts the negatively 
charged carboxyl away from the nucleotide (Fig. 7, a and b); if the Glu-118 rotamer observed 
in the wild-type holotoxin was to be maintained following reduction, its carboxyl group 
would be positioned within hydrogen-bonding distance of the N-ribose's 2′-hydroxyl (Fig. 
7e). This interaction is highly conserved within ART enzymes and is thought to promote 
nicotinamide scission by stabilizing the formation of an oxocarbenium ion intermediate (33). 
The movement of the carboxyl group caused by the E118D mutation helps explain why this 
otherwise relatively conservative substitution is inactivating in the ART enzymes (Fig. 7c). 
 
In the extended NAD+ conformation, the adenine base interleaves between the guanidinium 
group of Arg-13 and the indole ring of His-26. A similar interleaved interaction is seen in the 
NAD+-bound cholera toxin structure (15). In contrast, the semi-extended 
NAD+ conformation has the adenine base stacked atop Tyr-67 (Fig. 7b). The Y67A mutation 
was seen to abrogate catalytic activity in the ADP-ribosyltransferase assays using HsGαi3 as 
substrate (Fig. 7c), but ∼25% wild-type activity is retained by Y67F mutants suggesting it is 
the aromatic base-stacking role that is its more vital feature (Fig. 7c). Moreover, an S70W 
mutation, which would disrupt the adenosine-binding site of the semi-extended but not the 
extended conformation, also displayed minimal ADP-ribosyltransferase activity in vitro (Fig. 
7, band c) suggesting this conformation may play a role during catalysis. 
 
Several EcPltA residues located at the intersubunit interface of the holotoxin become solvent-
exposed following subunit dissociation; this includes Ile-111 on h5 and Ile-58 and Ser-56 on 
h3 (gray labels in Fig. 7b). To determine whether any such residues are also involved in 
protein interactions with the transfer target, they were mutated to large bulky residues to 
disrupt potential recognition interfaces. All mutations on the exterior face of h3 had no effect 
(Fig. 7c), whereas equivalent mutations on h5 (I111Y) were inactivating. This h5 helix is N-
terminal to the catalytic (E/Q)XE motif, a region of the ART domain that in cholera and C3-
like toxins corresponds to a conserved flexible loop between strands s4 and s5 known to be 
necessary for substrate recognition (34). 
 
 
Redox-induced structural changes 
 
We compared the inactive oxidized and active NAD+-bound states of EcPltA (Fig. 
7e; supplemental movie). This shows that the activation mechanism of pertussis-like toxins is 
fundamentally different from the loop-refolding mechanism of cholera toxin (15). The 
conserved intramolecular disulfide within the EcPltA-oxidized state (Cys-41–Cys-192) is 
located inside the NAD+-binding cleft directly above the catalytic glutamate (Glu-118), Cys-
192 being the C-terminal residue of the short inhibitory A2 helix. In the holotoxin, the 
binding pocket for the nicotinamide ring is filled by Phe-193 from hA2 (Fig. 7d); subsequent 
A2 backbone residues then rise to thread through the cleft with Arg-199 and Arg-200 
occupying the same site as the adenosine ring in the extended conformation (pink loop in Fig. 
7d). The A2 loop subsequently doubles back on itself before entering the pentamer pore; 
during this descent, it blocks the adenosine-binding site near helix 3 for the semi-extended 
conformation (Fig. 7b). The nucleotide-binding site of EcPltA is made from dynamic regions 
of the protein that move following release of the inhibitory C-terminal residues as well as 
regions that remain stationary. A static floor capable of accommodating either NAD+ or the 
A2 peptide includes the adenine base-interleaving residues Arg-13 and His-26 (Fig. 7a), the 
phosphate-binding nucleophile Arg-9, and the nicotinamide “STS” clasp equivalent residues. 
In contrast, structural movements are required to form the side walls of the NAD+-binding 
site. This is necessary as the occluding C-terminal helix is more bulky than the substrate 
nucleotide. 
 
After the redox-sensing disulfide is reduced, Cys-41 and the remainder of the active-site loop 
undergo an ∼2.5-Å rigid-body inward movement toward the adenosine ribose and phosphate 
(Fig. 7e). This loop movement carries the h2 helix with it until it abuts the 3′-hydroxyl of 
the N-ribose, and in doing so the catalytic residue His-35 (35) is shifted toward the scissile N-
glycosidic bond (Fig. 7, a and e) where it may interact with Glu-118. Following 
NAD+ binding, helix 3 pivots about its N terminus resulting in a maximal displacement from 
the oxidized form of ∼8.2 Å (Fig. 7e). This movement allows the side chains of Tyr-67 and 
Ile-63 to move in and neighbor the nicotinamide ring. These NAD+-binding associated 
movements are likely to be conserved features of activation within typhoid toxin and 
pertussis toxin. 
 
 
DISCUSSION 
 
We provide the structural details of the E. coli pertussis-like toxin in its intracellular reduced 
form, detailing different substrate-binding modes and the redox-induced structural changes 
that occur during activation. In the oxidized state, the disulfide-linked C terminus of the A 
subunit inactivates the protein by occluding the NAD+-binding site (Fig. 6), a mechanism 
clearly conserved within pertussis toxin as suggested by modeling studies (36). Loss of the 
inhibitory A2 domain from within the nucleotide-binding cleft allows significant lobe closure 
and reorganization of residues about NAD+particularly within helices h2, h3, and the active-
site loop. This contrasts with the activation mechanism of the cholera toxin whose A2 domain 
is largely external to the catalytic cleft and requires no lobe movements upon activation, but it 
involves significant loop restructuring (30). Our high-resolution co-crystal structure details 
NAD+ binding in two distinct conformations: the dominant extended conformation is similar 
to that observed in nucleotide-soaked CT crystals (30), and a second lower-occupancy semi-
extended conformation also exists and may play a role during catalysis as C-terminal h3 
mutations predicted to disrupt the base-stacked adenine abrogate activity. 
 
The residues within h2 are relatively well-conserved, suggesting the redox-induced 
movement of this structural element and the restructuring of the preceding active-site loop are 
a conserved features of pertussis-like proteins. In contrast, helices h3 and h5 show more 
significant structural divergence between the pertussis and the enterobacterial holotoxins, 
with these regions more likely involved in binding to the transfer target. GPCR binding is 
disrupted by pertussis toxin through modification of the Gαi residue Cys-351, and the toxin is 
highly specific and unable to modify mutants lacking this residue (Fig. 6). The extent to 
which pertussis-like toxins are conserved could have correlated with conservation of target 
chemistry, yet we show EcPlt does not modify cysteine residues within Gαi proteins but 
instead a lysine and asparagine several residues away. Moreover, our cAMP experiments 
confirmed that EcPltAB enters cells and inhibits the action of Gαi proteins via a residue other 
than Cys-351 (Fig. 4). This is not unprecedented; human poly(ADP-ribose) polymerase 1 
initiates polymer formation on C-terminal chromatin lysines (37), but ADP-ribosylation at 
such sites has not previously been described within bacterial toxins nor in human Gα 
subunits. Why would this site be targeted? GPCR:Gα-protein coupling occurs when the 
predominantly helical C terminus of the Gα subunit inserts into a pocket built from the 
cytoplasmic facing ends of the receptor TM helices. The co-complex structure of opsin in 
complex with the C terminus of transducin (38) shows that Cys-351 penetrates deep into the 
binding pocket, highlighting why pertussis toxin's modification would be incompatible with 
receptor coupling. As the C terminus of receptor-bound Gα subunits are predominantly 
helical, Asn-347 lies a turn beneath Cys-351 interacting with the same transmembrane helix 
(TM3). Lys-345 is on the opposing side of the G-protein's C terminus interfacing with TM6. 
Thus, both Asn-347 and Lys-345 reside closer to the cytoplasmic “mouth” of the receptor's 
binding pocket than Cys-351 when coupled to their cognate GPCRs. 
 
EcPltA-catalyzed ADP-ribosylation may thus block receptor recruitment of inhibitory 
heterotrimeric G-proteins using a related but distinct mechanism to that used by pertussis 
toxin. Our attempts to create an EcPlt-resistant Gαi3 subunit were partially successful 
(supplemental Fig. S5) and could be interpreted as indicating that the Asn-347 modification 
may dominate over the Lys-345 site in vivo. In vitro, both Lys-345 and Asn-347 were 
required for EcPltA to modify HsGαi3, so both residues may be involved in toxin:G-protein 
binding. Peptides consisting of the 10–20 C-terminal residues of HsGαi3 can act as minimal 
pertussis toxin substrate inhibitors (39) suggesting the entire protein is not necessarily 
required for recognition. Our work might imply that EcPlt has shifted its respective 
recognition motif within Gαi proteins several residues downstream from that of PT with Asn-
347 playing distinct roles in both EcPlt and PT toxins recognition interfaces; we note that 
Asn-347 appears to be more essential for the action of EcPlt as its mutation did not provide 
sufficient protection to reconstitute signaling in the presence of PT. Further work will be 
required to validate our reconstitution experiments; mutants that disrupt the toxin–G-protein 
interface may also influence GPCR binding and/or GTPase activity. 
 
Finally, pertussis toxin has become a valuable tool for dissecting GPCR pathways, and the 
identification of an expanded toolset of pertussis-like proteins with varied inhibitory 
mechanisms may permit additional experiments to be performed. Given the proven utility of 
PT in this role, it may be beneficial to further characterize the behavior of other pertussis-like 
toxins in reconstituted systems to fully understand how this toolset functions. 
 
 
EXPERIMENTAL PROCEDURES 
Materials 
All chemicals were purchased from Sigma unless otherwise stated. Mouse INSL5 was 
synthesized and purified at The Florey Institute of Neuroscience and Mental Health 
(Melbourne, Australia) by Dr. Akhter Hossain (40). FBS, DMEM Ham's/F-12, Lipofectamine 
2000, and PT were all from Life Technologies, Inc. AlphaScreen SureFire® ERK1/2 
phosphorylation kits, acceptor beads, and donor beads were all from PerkinElmer Life 
Sciences. 
 
Bioinformatic analysis and bacterial strains 
 
E. coli strains containing AB5-type toxin-like genes were identified from an E. colidataset 
(EcoDS) comprising 1700 genome sequenced strains deposited in the NCBI database up to 
January 2014 (56), using a querying dataset based on characterized AB5toxins (Art (16), 
Shiga (41), subtilase (42), and cholera (43) toxins). Sequence comparisons were performed 
using the FASTA36 package (44); ORFs with an amino acid sequence identity >75% of the 
toxin subunits were extracted from the public dataset. A neighbor-joining tree was generated 
using the concatenated AB toxin subunits with ClustalW (45). The phylogenetic group was 
determined using an in silicotriplex scheme (46, 47), and MLST analysis was performed 
according to a seven-gene scheme described previously (48). UPEC strain PA26B was 
isolated from a patient presenting with a urinary tract infection at the Princess Alexandra 
Hospital (Brisbane, Australia) (54). 
 
Toxin expression 
 
Toxin expression was induced by stressing PA26B cells and a control K12 laboratory strain, 
and overnight cultures grown at 37 °C were diluted 1:40 into 40 ml of LB broth without 
antibiotics and grown for 4 h at 37 °C before addition of mitomycin C or 10 mMH2O2. After 
24 h of growth, all proteins secreted into the media were harvested and clarified by passing 
through a 0.2-μm filter. 10 nM bovine catalase was added to the supernatant of cells stressed 
by H2O2. 
 
Cytotoxicity assay 
 
Kidney epithelial cells from the African green monkey (Vero cells) or human embryonic 
kidney (HEK293T) were expanded to 40–50% confluency in 10-cm2 dishes covered with 2 
ml of Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal calf serum. 
Cytotoxicity assays were performed by adding recombinant EcPltAB holotoxins at 50 μg/ml 
to 500 pg/ml. Cells were left for 18 h and then stained with crystal violet and imaged. The 
surface area covered by the cells was determined by the number of blue pixels within each 
image normalized against buffer controls. 
 
Cloning 
 
A co-expression vector for the EcPltAB toxin was created as in Ng et al. (12). Briefly, both 
the full-length EcPltA and EcPltB genes were chemically synthesized (GenScript), with the 
addition of restriction sites NdeI and XmaI and XbaI and XhoI flanking 
the EcPltA and EcPltB open reading frames, respectively. The EcPltA gene containing its 
native signal sequence was cloned directly into pBAD18. EcpltB was subcloned into pET-23 
(Novagen) via XbaI and XhoI sites, resulting in a protein with a C-terminal poly-His tag and 
N-terminal PelB signal sequence; this construct was used for the expression of 
unliganded EcPltB pentamer. To produce the co-expression vector for EcPltAB, the 
ribosome-binding site and EcPltB was excised from pET-23 using the XbaI and HindIII 
restriction sites prior to being cloned downstream of EcPltA within the pBAD vector. 
 
The catalytic domain of the pertussis toxins S1 subunit, EcPltA, and human HsGαi3proteins 
were cloned into a pET28 expression vector fused to a hexahistidine tag through a human 
rhinovirus 3C cleavage site. The constitutively active EcPltA construct encompassed residues 
5–181. The HsGαi3 constructs encompassed residues 034-354 or 005-354. Mutants used in 
enzymatic assays were created by oligonucleotide-directed mutagenesis followed by DpnI 
digestion of the parental vector, with all resulting constructs confirmed by sequencing. 
 
Protein expression and purification 
 
For protein expression, EcPltAB was transformed into E. coli BL21(DE3) cells and then 
grown in LB at 37 °C containing 100 μg/ml ampicillin to A600 = 0.6 followed by a 4-h 
induction at 37 °C with 0.2% L-arabinose. Cell culture pellet was collected and resuspended 
in HEPES-buffered saline (HBS) (20 mM HEPES, pH 7.0, 150 mM NaCl) and stored at −20 
°C. The cell pellet was thawed, lysed, and centrifuged with the supernatant collected and 
loaded onto 5 ml of nickel-Sepharose beads (GE Healthcare), equilibrated in 50 mM HEPES, 
pH 7.0, 250 mM NaCl, 60 mM imidazole. Unbound material was removed by washing with 
the same buffer. Protein was eluted with 1 M imidazole buffer (20 mM HEPES, pH 7.0, 250 
mM NaCl, 1 M imidazole), with 5-ml fractions collected. Fractions containing EcPltAB were 
pooled, buffer-exchanged into HBS, and loaded on a Superdex S200 16/60 gel filtration 
column (GE Healthcare) where it eluted with a molecular mass consistent with that of a 
heterohexamer (∼100 kDa). 
 
Protein expression of EcPltA constructs were performed in BL21 (DE3) E. coli cells that 
were grown at 37 °C in LB medium supplemented with 30 μg/ml kanamycin. After reaching 
an A600 nm of 0.6–0.8, the temperature was dropped to 18 °C, and the cells were induced for 
18 h with 0.2 mM isopropyl β-D-1-thiogalactopyranoside. Cells were harvested and 
resuspended in HBS with 20 mM imidazole and 1 mM TCEP, then lysed by adding 1 mg/ml 
lysozyme and DNase, and then sonicated. Cleared lysate was applied to a Ni-NTA affinity 
column and washed extensively before eluting in 20 mMHEPES, pH 7.0, 250 mM NaCl, 400 
mM imidazole, 1 mM TCEP. The protein's hexahistidine tag was cleaved by incubating the 
eluted protein with 0.1 mg/ml GST-fused HRV 3C overnight at 4 °C. The HRV 3C protease 
was removed by passing over 0.1 ml of GSH-agarose resin with the flow-through 
subsequently purified by gel filtration on a Superdex S75 16/60 (GE Healthcare). The 
constructs eluted as a single peak corresponding to monomeric EcPltA. The pertussis toxin's 
catalytic S1 domain was purified using a similar manner. 
 
Expression of the different HsGαi3 constructs was identical to that of EcPltA except they 
required 0.01% (v/v) Triton X-100 during HRV 3C cleavage, and the protein was buffer-
exchanged into 20 mM HEPES, 50 mM NaCl, 1 mM TCEP to allow HiTrap Q purification 
prior to gel filtration. When HsGαi3 mutants were being purified for enzymatic assays, 
chromatographic systems and columns were purged with two intervening dummy runs: one 
of 0.5 M NaOH followed by 1 M HEPES, pH 7.0. When required, HsGαi3ΔN was 
methylated using a reductive alkylation kit (Hampton Research HR2-434) or 
carbamidomethylated with iodoacetamide (Pierce 90034) according to the manufacturer's 
instructions prior to the ion-exchange column during purification. 
 
Enzymatic assay 
 
Activity assays were performed using 6-Biotin-17-NAD+ (BPS Biosciences 80610) as a 
substrate for the modification of different G-protein substrates. The resulting biotin adducts 
were visualized using streptactin-conjugated horseradish peroxidase (Bio-Rad 161-0381). 
Briefly each reaction mix contained ∼1 μM protein substrate, which consisted of 
recombinant HsGαi3, purified trimeric bovine brain G-proteins (EMD Millipore 371739), or 
whole Vero cell lysate. Standard assay conditions consisted of ∼1 μM G-protein in 20 
mM HEPES, pH 7.0, 140 mM NaCl, 5 mM TCEP, and 10 μM biotin-NAD+, which was 
incubated for 5 min at 37 °C with 20 nM toxin. Holotoxin assays were performed with up to 
100 mM TCEP to induce activation and consisted of PT purified from Bordetella lysate 
(Sigma P7208) or recombinant EcPltAB. Reactions were stopped by adding SDS-loading 
buffer and heating at 100 °C for 5 min before analysis by SDS-PAGE. Analysis by 2D gel 
electrophoresis was done by the Proteomics Facility, Monash University; samples were 
separated in the 1st dimension over broad PIG pH strip (pH 3–10) before separation in the 
second dimension by SDS-PAGE (gradient of 9–16% acrylamide). 1D and 2D gels were 
processed for analysis by Western blot; proteins were transferred to a membrane prior to 
being visualized using streptactin-HRP and Pierce chemiluminescence substrate. Assays 
performed with recombinantly produced G-proteins were subsequently stained by Coomassie 
to ensure equal loading. All assays were repeated three times to ensure reproducibility. 
Densitometry was performed using an Epson V700 scanner and data quantification via 
ImageQuant. 
 
Crystallization data collection and structure determination 
 
The EcPltAB holotoxin crystals were obtained by setting up 1:1 ratio hanging drop 
experiments with 16 mg/ml protein over a reservoir of 0.2 M MgCl2, 0.1 M Tris-HCl, pH 
8.5, 15% (w/v) polyethylene glycol 3350 at 293 K; crystals took 2–3 weeks to grew and were 
then harvested by flash-freezing in liquid nitrogen after soaking in a cryoprotectant solution 
containing an additional 25% (v/v) glycerol prior to data collection. EcPltAB crystals 
diffracted to 2.35 Å in space group P65 with one heterohexamer in the asymmetric unit, and 
initial maps were generated using the lower AB5 section of the typhoid toxin (7) as a 
molecular replacement model (49) in the program Phaser (50). The resulting electron density 
allowed rounds of manual building and refinement using the programs COOT (51) and 
PHENIX (49). Because of the moderate resolution, NCS constraints were maintained 
throughout refinement, as releasing restraints did not result in significant improvements 
in Rfree. The final model encompasses residues 1–114 across all five protomer B subunits 
and residues 4–226 in the A subunit. 
 
The reduced EcPltA(Q116D,E118D) mutant at 6–8 mg/ml was complexed with 20 
mMNAD+ for 30 min before setting up in hanging drop crystallization experiments using a 
1:1 ratio at 277 K. Clusters of plate-like crystals grew within 2–3 days over reservoirs 
containing 4–7% (v/v) polyethylene glycol, 0.1 M Tris, pH 8.5, and 150 mM Li2SO4. 
Crystals clusters were broken into single pieces prior to freezing in a reservoir complemented 
with 25% (v/v) glycerol and flash-frozen in liquid nitrogen, subsequently diffracting in a 
monoclinic space group to 1.8 Å with four molecules in the asymmetric unit. A molecular 
replacement solution was obtained using a trimmed version of the holotoxin's A1 subunit as a 
model with four molecules found within the asymmetric unit. In protomers A–D, clear 
electron density was observed for residues 4–174, and there were few differences in the 
Cα backbone structure among protomers except for a shift in protomer D within the loop C-
terminal to h3. The final model contains four NAD+ molecules and all but the C-terminal 
residue of the construct. 
 
Data completeness for the EcPltA in space group P1 was a little lower than ideal. When PT or 
EcEPlt dissociates from their B subunits, they mimic unfolded proteins to translocate toward 
the cytosol. In such structures h5 is highly flexible so crystals often grew as oddly shaped 
clusters that needed to be fragmented. In the four molecules in the asymmetric unit, the h5 
loop adopts different forms; moreover, such conformations varied when data were collected 
at different points in the crystal. This structural complexity caused issues for merging of 
datasets, and crystals showed some radiation damage after 150–200°, and the dataset was 
collected from multiple points on a single crystal. 
 
Glycan array analysis 
 
Purified EcPltAB protein at 1 or 100 μg/ml was applied to a PA_v51 glycan microarray at the 
Consortium of Functional Glycomics Protein–Glycan Interaction Core at Emory University, 
and binding was detected using Alexa488-conjugated anti-hexahistidine antibody. The data 
are reported as average relative fluorescence units of four of six replicates (after removal of 
the highest and lowest values) for each glycan represented on the array. 
 
Mass spectrometry analysis 
 
HsGαi3 at 2 mg/ml was treated for 1 h with a 100:1 molar ratio of EcPltA in 20 mMHEPES, 
150 mM NaCl, 2.5 mM NAD+, 0.5 mM TCEP, pH 7.5. After the reaction, the protein was 
diluted into 20 mM HEPES, 50 mM NaCl and then bound to a HiTrap Q column and eluted 
under a 20-ml gradient to 1 M NaCl to remove unreacted NAD+. The reaction product was 
diluted into 100 mM (NH4)HCO3 and heated to 95 °C for 5 min; after cooling to room 
temperature, the sample was divided in two with fresh chloroacetamide added to one fraction 
at a final concentration of 5 mM for 30 min. Trypsin was then added at a 1:50 ratio with the 
digestion allowed to proceed for 18 h at 37 °C, and the digestion was finally quenched with 
formic acid at a final concentration of 0.25% (v/v). The resulting peptides were analyzed by 
LC-MS/MS using the QExactive mass spectrometer (Thermo Fisher Scientific, Bremen, 
Germany) coupled on line with an RSLC nano-HPLC (Ultimate 3000, Thermo Fisher 
Scientific) (52). MS/MS data analysis was done with MaxQuant software (build 1.5.2.8); MS 
data were analyzed using MaxQuant (53) searched against the human and E. coli K12 strain 
protein sequences taken from UniprotKB (March, 2015). ADP-ribosylation was defined as 
modification of a mass of 541.0611088 Da on with diagnostic peaks of 438.03699 (m8), 
348.07036 (m6), 250.09346 (m3), and 136.06177 (m1) and the corresponding natural loss 
peaks. The search parameters include enzyme specificity of trypsin with three missed 
cleavages. Search parameters also allowed for cysteine carbamidomethylation, methionine 
oxidation, or ADP-ribosylation on cysteine, lysine, arginine, glutamate, aspartate, and 
asparagine. All other search parameters were set to the default settings. 
 
Cell culture and transient transfection 
 
CHO cells stably expressing RXFP4 (CHO-RXFP4) were a gift from Associate Professor 
Ross Bathgate (Florey Institute of Neuroscience and Mental Health, Melbourne, Australia). 
Cells were grown and maintained in 175-cm2 flasks in DMEM/F-12 medium supplemented 
with 5% (v/v) fetal bovine serum (FBS) at 37 °C in humidified air containing 5% CO2. 
cDNA constructs for G-protein α subunits (GαoA, GαoB, Gαi1, Gαi2, or Gαi3) containing 
the C351I mutation were from the cDNA Resource Center (Bloomsberg, 
PA). HsGαi3 containing K345A and N347A mutations were generated via site-directed 
mutagenesis using wild-type HsGαi3 pcDNA3 vector as template. HsGαi/oconstructs 
carrying the mutations were transiently transfected into CHO-RXFP4 cells grown on 6-well 
plates using Lipofectamine 2000 as per the manufacturer's protocol. 
 
ERK1/2 phosphorylation 
 
18 h after transfection, CHO-RXFP4 cells were trypsinized and seeded onto 96-well plates at 
a density of ∼50,000 cells per well and incubated for 6–8 h in complete media to allow cell 
adhesion. Cells were then incubated with PT, EcPltAB, or control (serum-free DMEM/F-12) 
for 18 h before stimulation with mouse INSL5 (0.1 to 100 nM) for 5 min and then lysed. 
Phosphorylation of ERK1/2 (Thr-202/Tyr-204) was detected using the AlphaScreen 
SureFire® kit. In brief, 4 μl of cell lysates was added to a white 384-well microplate 
(ProxiPlate; PerkinElmer Life Sciences) containing 5 μl of acceptor bead mix (40 parts 
reaction buffer/10 parts activation buffer/1 part protein A acceptor beads) and incubated for 2 
h at 23 °C. Then, 2 μl of donor bead mix (20 parts dilution buffer/1 part streptavidin-coated 
donor beads) was added and incubated for 2 h at 23 °C. All additions and incubations were 
carried out under low light conditions to avoid photobleaching. Fluorescence readings were 
made using the Envision multilabel plate reader (PerkinElmer Life Sciences; excitation = 680 
nm; emission = 520–620 nm). ERK1/2 phosphorylation is expressed as a percentage response 
to 10% (v/v) FBS (positive control). 
 
Inhibition of cAMP accumulation 
 
18 h after transfection, CHO-RXFP4 cells were trypsinized and seeded onto 96-well plates at 
a density of ∼50,000 cells per well and incubated for 6–8 h in complete media to allow cell 
adhesion. Cells were then incubated with PT, EcPltAB, or control (serum-free DMEM/F-12 
medium) for 18 h. On the day of experiment, we changed the medium to Hanks' balanced salt 
solution supplemented with 500 μM isobutylmethylxanthine, 5 mM HEPES, and 0.1% (w/v) 
BSA and equilibrated for 1 h at 37 °C. Cells were treated with INSL5 (100 nM) for 15 min, 
followed by 30 min of forskolin stimulation and then lysed with 100% ice-cold ethanol. Once 
ethanol has evaporated, cAMP was resuspended in 100 μl of lysis buffer containing 0.3% 
(v/v) Tween 20, 5 mM HEPES, and 0.1% (w/v) BSA. The amount of cAMP generated by 
forskolin and its inhibition by INSL5 was measured using a homogeneous time-resolved 
fluorescence resonance energy transfer LANCE cAMP kit (PerkinElmer Life Sciences) as per 
the manufacturer's protocol. 
 
 
 
  
Figure 1. 
 
 
E. coli AB5 toxins. Shown is a cladogram of AB5 toxin sequences identified in genome sequenced E. coli strains 
available on the NCBI database. Archetype sequences from the querying dataset are indicated with an asterisk. E. 
coli strains harboring more than one AB5 group are indicated by a red star. The inner circle represents the E. 
coliphylogenetic groups (A, B1, B2, and D). Additional color-coded circles indicate the place, year, and source of 
each strain, as well as the associated infection (where known). Because Shiga toxigenic E. coli strains are over-
represented in the NCBI database, only archetypical Shiga toxin variants are presented. The EcPltA toxin focused on 
in this study is highlighted with a blue star. A schematic of the A and B subunit domain displayed with the positions 
of the intramolecular disulfides (yellow) and the inhibitory C terminus (pink) is at the bottom of the figure. Inset, an 
expanded view of the pertussis toxin branch. A complete overview of all Shiga toxin variants and their associated 
strains is presented in supplemental Fig. S1. 
 
 
 
  
Figure 2 
 
 
 
Cytotoxicity of recombinant EcPltAB. 18 h after treatment with buffer or different concentrations of EcPltAB, Vero 
cells were stained and imaged. a,representative images for untreated controls (left) and 50 ng/ml EcPltAB (right) are 
shown. b, ADP-ribosyltransferase assays in which pertussis toxin or EcPltAB were used to modify different protein 
substrates, including trimeric G-protein extracts, recombinant human Gαi3, or Vero cell lysates. Reactions at 37 °C 
were performed in the presence of biotin-NAD+ and then quenched after 5 min, separated by SDS-PAGE, transferred 
to a Western blotting membrane, and imaged with either luminescence following streptactin-HRP exposure (left) or 
Coomassie (right). c, Western blottings showing the incubation of ExPEC culture medium with NAD+-biotin with and 
without the presence of HsGαi3ΔN. d, Vero cells were imaged in a similar manner to those in a were monitored for the 
degree of cell growth relative to buffer controls following exposure to different concentrations of EcPltAB or A 
subunit mutants. Surface area is calculated from the percentage of each image stained by crystal violet. Data represent 
the mean ± S.D. from three replicates        
 
 
 
 
  
Figure 3 
 
 
Activity assays for EcPltAB. a, ADP-ribosyltransferase assays similar to those used in Fig. 2using biotinylated 
NAD+ as a substrate to modify recombinant HsGαi3ΔN PT (left) and EcPltAB (right) holotoxins were monitored for 
activity for 5 min at 37 °C in the presence of 10 mM (+) or 100 mM (++) TCEP and with or without 10 
mM ATP. b, EcPltAB activation in the presence of different ratios of reduced (GSH) or oxidized (GSSG) glutathione 
within the ADP-ribosylation assay. c, 2D isoelectric focusing separation of different Gaiisoforms isolated from bovine 
brain extract following treatment with EcPltAB or PT indicate multiple Gai isoforms act as substrates      
 
  
Figure 4 
 
 
Proposed model of the pertussis-like toxins transfer target. a, structure of opsin in complex with the C terminus of 
transducin (Scheerer et al. (38), Protein Data Bank code 3DQD); their K345L mutant was reverted to lysine for this 
figure. Gαi3 is shown in teal; the position of the C terminus and ADP-ribosylated residues discussed in text are shown. 
The plasma membrane and GPCR (green) are at the top. b, ADP-ribosyltransferase assays using EcPltA or pertussis 
toxin in which potential acceptor cysteines within Gαi3ΔN were mutated to serine; or c, following iodoacetamide and 
lysine methylation; d, mutation of Lys-345; or e, Asn-346 and Asn-347 to alanine     
 
 
  
Figure 5 
 
 
EcPltAB disrupts G-protein-coupled signaling. RXFP4 recruits Gi/o α subunits upon ligand activation. PT 
pretreatment abolishes INSL5-stimulated ERK1/2 phosphorylation, and this is rescued to differing degrees by 
transfection of individual PT-insensitive Gi/o mutants. a,Chinese hamster ovary-RXFP4 cells were transiently 
transfected with pcDNA3 vector control, or b–f, Gi/o constructs carrying the C351I mutation (mGαoA, mGαoB, mGαi1, 
mGαi2, or mGαi3). Blockade of the response to PT but not EcPltAB pretreatment was rescued by transfection of the 
mutant G-proteins. Cells were stimulated with mouse INSL5 alone (0.1 to 100 nM) or after pretreatment with PT (100 
ng/ml) or EcPltAB (100 ng/ml). Data points represent mean ± S.E. of three independent experiments and are expressed 
as the % response of the positive control (10% v/v FBS). Veh, vehicle                  
 
 
 
 
  
Figure 6 
 
 
Activation mechanisms of EcPlt and cholera toxin. a, schematic representation of the EcPltAB holotoxin in which 
α-helices are colored marine, β-strands wheat, and loop regions green. The C-terminal A2 domain is highlighted 
in pink showing its interaction with the B subunits of the glycan-binding pentamer (gray). b, schematic representation 
highlighting the holotoxin's EcPltA subunit. The conserved redox-sensing disulfide is labeled, and the rough position 
of the B-pentamer is shown as a partially transparent structure. Predicted potential proteolytic sites are shown with 
partially transparent scissors, and the C terminus is marked Ct. c, reduced active NAD+ co-complex with all secondary 
structural elements labeled. The enzymatically cleaved N-glycosidic bond cleaved during the course of the reaction 
is highlighted                 
 
 
 
  
Figure 7 
 
 
NAD+-binding site of EcPltA. a, structure of EcPltA with NAD+bound in the extended conformation; residues 
investigated for their role in binding and catalysis are labeled, as are the nicotinamide STS-clasp equivalent 
residues 52ATT54. b,structure of the semi-extended NAD+ conformation, approximate position of occluding residue 
mutants are shown in gray. c, ADP-ribosyltransferase assay response relative to wild-type protein for various point 
mutants within the NAD+-binding site. Error barsare the S.D. of three independent replicates. d, depiction of where the 
residues important for NAD+ binding are located in the oxidized holotoxin and their interactions with the occluding A2 
helix (pink). e, overlay highlighting the structural changes occurring during activation/NAD+binding. The semi-
extended NAD+-bound structure (blue helices and orange loop) is compared with the oxidized holotoxin (cyan 
helices and yellow loop)                   
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